Literature DB >> 20540569

Identification of noninvasive biomarkers for alcohol-induced liver disease using urinary metabolomics and the Ppara-null mouse.

Soumen K Manna1, Andrew D Patterson, Qian Yang, Kristopher W Krausz, Henghong Li, Jeffrey R Idle, Albert J Fornace, Frank J Gonzalez.   

Abstract

Alcohol-induced liver disease (ALD) is a leading cause of nonaccident-related deaths in the United States. Although liver damage caused by ALD is reversible when discovered at the earlier stages, current risk assessment tools are relatively nonspecific. Identification of an early specific signature of ALD would aid in therapeutic intervention and recovery. In this study, the metabolic changes associated with ALD were examined using alcohol-fed male Ppara-null mouse as a model of ALD. Principal components analysis of the mass spectrometry-based urinary metabolic profile showed that alcohol-treated wild-type and Ppara-null mice could be distinguished from control animals without information on history of alcohol consumption. The urinary excretion of ethyl-sulfate, ethyl-beta-d-glucuronide, 4-hydroxyphenylacetic acid, and 4-hydroxyphenylacetic acid sulfate was elevated and that of the 2-hydroxyphenylacetic acid, adipic acid, and pimelic acid was depleted during alcohol treatment in both wild-type and the Ppara-null mice albeit to different extents. However, indole-3-lactic acid was exclusively elevated by alcohol exposure in Ppara-null mice. The elevation of indole-3-lactic acid is mechanistically related to the molecular events associated with development of ALD in alcohol-treated Ppara-null mice. This study demonstrated the ability of a metabolomics approach to identify early, noninvasive biomarkers of ALD pathogenesis in Ppara-null mouse model.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20540569      PMCID: PMC2917755          DOI: 10.1021/pr100452b

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  37 in total

1.  Human urinary metabolomic profile of PPARalpha induced fatty acid beta-oxidation.

Authors:  Andrew D Patterson; Ondrej Slanar; Kristopher W Krausz; Fei Li; Constance C Höfer; Frantisek Perlík; Frank J Gonzalez; Jeffrey R Idle
Journal:  J Proteome Res       Date:  2009-09       Impact factor: 4.466

2.  Regulation of mouse hepatic alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, a key enzyme in the tryptophan-nicotinamide adenine dinucleotide pathway, by hepatocyte nuclear factor 4alpha and peroxisome proliferator-activated receptor alpha.

Authors:  Mariko Shin; Insook Kim; Yusuke Inoue; Shioko Kimura; Frank J Gonzalez
Journal:  Mol Pharmacol       Date:  2006-06-28       Impact factor: 4.436

3.  Effect of chronic intake of ethanol on pyridine nucleotide levels in rat liver and kidney.

Authors:  H Kalant; J M Khanna; J Loth
Journal:  Can J Physiol Pharmacol       Date:  1970-08       Impact factor: 2.273

4.  Peroxisome proliferator activated receptor-alpha expression in human liver.

Authors:  C N Palmer; M H Hsu; K J Griffin; J L Raucy; E F Johnson
Journal:  Mol Pharmacol       Date:  1998-01       Impact factor: 4.436

5.  Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor.

Authors:  Hai-Lin Fang; Stephen C Strom; Hongbo Cai; Charles N Falany; Thomas A Kocarek; Melissa Runge-Morris
Journal:  Mol Pharmacol       Date:  2005-01-05       Impact factor: 4.436

6.  The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants.

Authors:  A Sapone; J M Peters; S Sakai; S Tomita; S S Papiha; R Dai; F K Friedman; F J Gonzalez
Journal:  Pharmacogenetics       Date:  2000-06

Review 7.  Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyl-transferases.

Authors:  J Zhou; J Zhang; W Xie
Journal:  Curr Drug Metab       Date:  2005-08       Impact factor: 3.731

8.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.

Authors:  Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

9.  Polymorphisms in the peroxisome proliferator activated receptor alpha gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians.

Authors:  Min-Jeong Shin; Alka M Kanaya; Ronald M Krauss
Journal:  Atherosclerosis       Date:  2007-12-03       Impact factor: 5.162

10.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators.

Authors:  S S Lee; T Pineau; J Drago; E J Lee; J W Owens; D L Kroetz; P M Fernandez-Salguero; H Westphal; F J Gonzalez
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

View more
  26 in total

Review 1.  Future perspectives of Chinese medical formulae: chinmedomics as an effector.

Authors:  Xijun Wang; Aihua Zhang; Hui Sun
Journal:  OMICS       Date:  2012-06-26

Review 2.  The Hepatic Lipidome: A Gateway to Understanding the Pathogenes is of Alcohol-Induced Fatty Liver.

Authors:  Robin D Clugston; Madeleine A Gao; William S Blaner
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

Review 3.  Transgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicity.

Authors:  Frank J Gonzalez; Zhong-Ze Fang; Xiaochao Ma
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-04-02       Impact factor: 4.481

Review 4.  Extracellular vesicles as potential biomarkers for alcohol- and drug-induced liver injury and their therapeutic applications.

Authors:  Young-Eun Cho; Byoung-Joon Song; Mohammed Akbar; Moon-Chang Baek
Journal:  Pharmacol Ther       Date:  2018-04-03       Impact factor: 12.310

5.  Investigation of chronic alcohol consumption in rodents via ultra-high-performance liquid chromatography-mass spectrometry based metabolite profiling.

Authors:  Helen G Gika; Cheng Ji; Georgios A Theodoridis; Filippos Michopoulos; Neil Kaplowitz; Ian D Wilson
Journal:  J Chromatogr A       Date:  2012-03-03       Impact factor: 4.759

Review 6.  Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Metabolites       Date:  2020-01-28

7.  UPLC-MS-based urine metabolomics reveals indole-3-lactic acid and phenyllactic acid as conserved biomarkers for alcohol-induced liver disease in the Ppara-null mouse model.

Authors:  Soumen K Manna; Andrew D Patterson; Qian Yang; Kristopher W Krausz; Jeffrey R Idle; Albert J Fornace; Frank J Gonzalez
Journal:  J Proteome Res       Date:  2011-07-28       Impact factor: 4.466

8.  PPARβ/δ modulates ethanol-induced hepatic effects by decreasing pyridoxal kinase activity.

Authors:  Maryam Goudarzi; Takayuki Koga; Combiz Khozoie; Tytus D Mak; Boo-Hyon Kang; Albert J Fornace; Jeffrey M Peters
Journal:  Toxicology       Date:  2013-07-10       Impact factor: 4.221

9.  Modulation of fatty acid and bile acid metabolism by peroxisome proliferator-activated receptor α protects against alcoholic liver disease.

Authors:  Heng-Hong Li; John B Tyburski; Yi-Wen Wang; Steve Strawn; Bo-Hyun Moon; Bhaskar V S Kallakury; Frank J Gonzalez; Albert J Fornace
Journal:  Alcohol Clin Exp Res       Date:  2014-04-28       Impact factor: 3.455

Review 10.  The metabolomic window into hepatobiliary disease.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  J Hepatol       Date:  2013-05-25       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.